Probiodrug AG Provides Further Insights into Science and Development of Glutaminyl Cyclase Inhibitor Development at 2013 Alzheimer’s Association International Conference

Published: Jul 08, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Probiodrug AG (Probiodrug) announced that it will be making two poster and two oral presentations at the upcoming Alzheimer’s Association International Conference in Boston, MA July 13 - 18, 2013. These presentations will provide further insight into the rationale of targeting QC for the treatment of Alzheimer’s disease. In addition, it will be presenting collaborative data on the efficacy and safety in animal models of a passive immunotherapy against Pyroglutamate-3 Abeta. Moreover, these presentations will provide results from first human studies with PQ912, a small molecule QC-inhibitor, in healthy elderly.

Help employers find you! Check out all the jobs and post your resume.

Back to news